Evaluation of efficacy and safety of human insulin (Novo) in the treatment of insulin-dependent diabetes mellitus: A double-blind, multicenter clinical trial

J. Karam, S. Brink, R. Clements, L. Miller, Philip Raskin

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

The safety and efficacy of human insulin (Novo) were evaluated in a double-blind, parallel, multicenter trial in which 47 insulin-dependent diabetic patients were randomly divided into two equal groups and treated with either purified pork or human insulin (Actrapid and Monotard, Novo) for 12 wk. Mean levels of fasting plasma glucose, glycohemoglobin, and daily insulin dosages showed no statistical differences between the two groups, and there was no significant difference in the incidence of hypoglycemic reactions. The results from this clinical trial indicate that human insulin, prepared by enzymatic transpeptidation of pork insulin, appears to be as safe and efficacious as purified pork insulin in the treatment of insulin-dependent diabetes mellitus.

Original languageEnglish (US)
Pages (from-to)56-60
Number of pages5
JournalDiabetes care
Volume6
Issue numberSuppl. 1
StatePublished - May 20 1983

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Fingerprint Dive into the research topics of 'Evaluation of efficacy and safety of human insulin (Novo) in the treatment of insulin-dependent diabetes mellitus: A double-blind, multicenter clinical trial'. Together they form a unique fingerprint.

  • Cite this